Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects

NCT05399459 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05399459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05399459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
August 9, 2022
Completion date
January 19, 2024
Enrollment
897 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

migraine